Linda Alunkal

Form D signer

Linda Alunkal

Chief Executive Officer at BioLattice Ophthalmics

Form D signer

Capital raised by BioLattice Ophthalmics

$575K+$575K latest round

1 Form D filing · first filed Mar 2026 · Philadelphia, PA

CURRENT ROLE: Chief Executive Officer
SECTOR: Biotech
COMPANY FILINGS: 1
TEAM ON FILE: 2
FOUNDED: 2023
30D INTEREST: —

Career

1 company on file · founded 2023

BioLattice OphthalmicsBiotech · Philadelphia, PAsince 2023

Chief Executive Officer

Signatory on BioLattice Ophthalmics's Form D filings · $575K raised across 1

Company filings

via EDGAR · Form D for BioLattice Ophthalmics1

DateCompanyFormAmountRole on filing

Mar 6, 2026BioLattice OphthalmicsForm D+$575KChief Executive Officer

Form DMar 6, 2026 · BioLattice Ophthalmics+$575Kas Chief Executive Officer

Overview

Last filing Mar 6, 2026

Linda Alunkal is on file as Chief Executive Officer at BioLattice Ophthalmics in Philadelphia, PA. BioLattice Ophthalmics has 1 Form D filing on record, $575K raised in total. Linda Alunkal appears as a signatory on the company's filings.

LinkedIn profile

Teammates

BioLattice Ophthalmics · 1

Gregory JacksonDirector

Products

BioLattice Ophthalmics · 1

CorneaClearOphthalmic implant / medical device

An engineered synthetic cornea: a biocompatible, room-temperature-stable implant designed as an alternative to donor corneal tissue for corneal replacement surgery.